Who Paid My Doc
Francesco Grasso
Towson, MD Medical Doctor
NPI 1316930712 CMS profile 196126
6569 N Charles St, Suite 502, Towson, MD 21204
General payments
$30,783
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Francesco Grasso of Towson, MD is reported in the CMS Open Payments database as having received $30,783 across 52 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $17,729 | 6 | |
| 2024 | General | $1,098 | 8 | |
| 2023 | General | $1,016 | 7 | |
| 2022 | General | $986 | 13 | |
| 2021 | General | $580 | 4 | |
| 2020 | General | $1,976 | 3 | |
| 2019 | General | $7,399 | 11 |
Beside peers
- Francesco Grasso
- Maryland median
- Middle half of Maryland
- National median
In program year 2025, general payments to Francesco Grasso were reported at $17,729. Among 20,588 Maryland profiles paid that year, the median was $166 and the middle half received between $51 and $580.
Show as a table
| Year | Francesco Grasso | Maryland median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,399 | $165 | $50–$633 | $163 |
| 2020 | $1,976 | $114 | $37–$407 | $114 |
| 2021 | $580 | $130 | $36–$480 | $132 |
| 2022 | $986 | $150 | $45–$529 | $149 |
| 2023 | $1,016 | $155 | $47–$557 | $160 |
| 2024 | $1,098 | $169 | $53–$600 | $164 |
| 2025 | $17,729 | $166 | $51–$580 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
66
Drug cost
$7,923
Branded share of claims
19.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cortifoam Hydrocortisone Acetate | Brand | 13 | $5,660 | |
| Colestipol Hcl | Generic | 26 | $1,845 | |
| Hydrocortisone | Generic | 16 | $384 | |
| Tramadol Hcl | Generic | 11 | $35 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,507 Part D prescribers listed as Colorectal Surgery (Proctology); they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 38 billing codesPaid by Medicare
$117,425
Medicare patients
324
Services billed
737
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 73% | |
| Arthritis | 44% | |
| Diabetes | 25% | |
| Depression | 24% | |
| Ischemic heart disease | 23% | |
| Cancer | 23% | |
| Chronic kidney disease | 19% | |
| Atrial fibrillation | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
52 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.